Loading...
Loading...
Available on 1 platform
Sign in to view source links and access this dataset
2706 patients with chronic obstructive pulmonary disease (COPD) or primary lung cancer (PLC) from three Shanghai hospitals were studied. The retrospective analysis quantified inappropriate tumor marker (TM) requests, finding 58.27–79.06% of 12,496–16,956 requests were unsuitable, costing 650,200–1,014,156 yuan. The dataset supports analysis of TM overuse, associated costs, and guideline adherence in pulmonary care.
License is CC0-1.0. The specific data schema (columns, file formats, sample data) is not provided in the input, which may require contacting the author or platform for the raw dataset structure.